Bulletin from Extraordinary General Meeting in Isofol Medical AB (publ) held on February 28, 2023
Today on February 28, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its Extraordinary General Meeting (“EGM”) at which the following principal resolutions were passed.
Election of board members and remuneration to the board of directors
The EGM resolved, in accordance with the shareholders’ (those requested the EGM to be convened) proposal, that the number of members of the board of directors shall be three without deputies.
The EGM elected, in accordance with the shareholders’ (those requested the EGM to be convened) proposal, Mats Franzén, Jonas Pedersén and Jan-Eric Österlund as new members of the board of directors. Mats Franzén was elected new chairman of the board of directors. All elections for the period until the end of the next Annual General Meeting.
The EGM further resolved to, in accordance with the shareholders’ (those requested the EGM to be convened) proposal, that newly elected board members shall receive remuneration in accordance with the remuneration levels resolved by the Annual General Meeting 2022, proportionally to the term of office.
For more information, please contact
Isofol Medical AB (publ)
Mats Franzén, chairman of the Board
E-mail: [email protected]
Phone: +46 (0) 704-472909
The information was submitted for publication, through the agency of the contact person set out above, at 16.00 CET, on February 28, 2023.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a clinical-stage biotechnology company that has focused its operations on developing and improving the current standard treatment for patients suffering from cancer by increasing treatment efficacy through the use of cytostatics. Isofol’s ambition was to develop a drug for first-line treatment of advanced colorectal cancer (mCRC), thereby seeking to improve the current clinical practice by realizing the full strength of 5-FU with the addition of arfolitixorin. Isofol has an exclusive global licensing agreement with Merck & Cie in Schaffhausen, Switzerland, to develop and commercialize arfolitixorin in oncology. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
